{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:49:05Z","timestamp":1777636145676,"version":"3.51.4"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2020.10014.BD"],"award-info":[{"award-number":["2020.10014.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/BIM\/04293\/2019"],"award-info":[{"award-number":["UID\/BIM\/04293\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023978","name":"Comiss\u00e3o de Coordena\u00e7\u00e3o e Desenvolvimento Regional do Norte","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}],"id":[{"id":"10.13039\/501100023978","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13346-024-01775-8","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T15:16:41Z","timestamp":1736176601000},"page":"2794-2813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Nanostructured lipid carriers for enhanced batimastat delivery across the blood\u2013brain barrier: an in vitro study for glioblastoma treatment"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4753-2197","authenticated-orcid":false,"given":"Miguel","family":"Horta","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9607-6998","authenticated-orcid":false,"given":"Paula","family":"Soares","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5763-7553","authenticated-orcid":false,"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-1245","authenticated-orcid":false,"given":"Catarina","family":"Leite Pereira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5838-9659","authenticated-orcid":false,"given":"Raquel T.","family":"Lima","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"issue":"4","key":"1775_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3390\/cancers12040937","volume":"12","author":"V Rajaratnam","year":"2020","unstructured":"Rajaratnam V, et al. Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. Cancers. 2020;12(4):937. https:\/\/doi.org\/10.3390\/cancers12040937.","journal-title":"Cancers"},{"issue":"7","key":"1775_CR2","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3390\/curroncol31070296","volume":"31","author":"M Jezierza\u0144ski","year":"2024","unstructured":"Jezierza\u0144ski M, et al. Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme\u2014A Literature Review and Clinical Outcomes. Curr Oncol. 2024;31(7):3994\u20134002. https:\/\/doi.org\/10.3390\/curroncol31070296.","journal-title":"Curr Oncol"},{"issue":"5 Suppl","key":"1775_CR3","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","volume":"20","author":"ME Davis","year":"2016","unstructured":"Davis ME. Glioblastoma: Overview of Disease and Treatment. Clin J Oncol Nurs. 2016;20(5 Suppl):S2-8. https:\/\/doi.org\/10.1188\/16.CJON.S1.2-8.","journal-title":"Clin J Oncol Nurs"},{"key":"1775_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jconrel.2022.11.024","volume":"353","author":"C Martins","year":"2023","unstructured":"Martins C, et al. Glioblastoma immuno-endothelial multicellular microtissue as a 3D in vitro evaluation tool of anti-cancer nano-therapeutics. J Control Release. 2023;353:77\u201395. https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.024.","journal-title":"J Control Release"},{"issue":"3","key":"1775_CR5","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.7150\/thno.38147","volume":"10","author":"M Zhao","year":"2020","unstructured":"Zhao M, et al. Nanocarrier-based drug combination therapy for glioblastoma. Theranostics. 2020;10(3):1355\u201372. https:\/\/doi.org\/10.7150\/thno.38147.","journal-title":"Theranostics"},{"issue":"3","key":"1775_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1124\/pr.117.014944","volume":"70","author":"A Shergalis","year":"2018","unstructured":"Shergalis A, et al. Current Challenges and Opportunities in Treating Glioblastoma. Pharmacol Rev. 2018;70(3):412\u201345. https:\/\/doi.org\/10.1124\/pr.117.014944.","journal-title":"Pharmacol Rev"},{"key":"1775_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semcdb.2015.01.002","volume":"38","author":"Y Serlin","year":"2015","unstructured":"Serlin Y, et al. Anatomy and physiology of the blood-brain barrier. Semin Cell Dev Biol. 2015;38:2\u20136. https:\/\/doi.org\/10.1016\/j.semcdb.2015.01.002.","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"1775_CR8","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a020412","volume":"7","author":"R Daneman","year":"2015","unstructured":"Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1): a020412. https:\/\/doi.org\/10.1101\/cshperspect.a020412.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"1775_CR9","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1039\/c4nr04853a","volume":"7","author":"S Dixit","year":"2015","unstructured":"Dixit S, et al. Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. Nanoscale. 2015;7(5):1782\u201390. https:\/\/doi.org\/10.1039\/c4nr04853a.","journal-title":"Nanoscale"},{"issue":"2","key":"1775_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3109\/10611861003734001","volume":"19","author":"K Ulbrich","year":"2011","unstructured":"Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target. 2011;19(2):125\u201332. https:\/\/doi.org\/10.3109\/10611861003734001.","journal-title":"J Drug Target"},{"issue":"36","key":"1775_CR11","doi-asserted-by":"publisher","first-page":"9171","DOI":"10.1016\/j.biomaterials.2013.08.039","volume":"34","author":"B Zhang","year":"2013","unstructured":"Zhang B, et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials. 2013;34(36):9171\u201382. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.08.039.","journal-title":"Biomaterials"},{"issue":"3","key":"1775_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2217\/nnm.11.98","volume":"7","author":"G Tosi","year":"2012","unstructured":"Tosi G, et al. Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? Nanomedicine (Lond). 2012;7(3):365\u201382. https:\/\/doi.org\/10.2217\/nnm.11.98.","journal-title":"Nanomedicine (Lond)"},{"issue":"5","key":"1775_CR13","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1021\/acsnano.7b08172","volume":"12","author":"L You","year":"2018","unstructured":"You L, et al. Targeted Brain Delivery of Rabies Virus Glycoprotein 29-Modified Deferoxamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Mice. ACS Nano. 2018;12(5):4123\u201339. https:\/\/doi.org\/10.1021\/acsnano.7b08172.","journal-title":"ACS Nano"},{"issue":"2","key":"1775_CR14","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.ddtec.2011.12.002","volume":"9","author":"PJ Gaillard","year":"2012","unstructured":"Gaillard PJ, et al. Enhanced brain drug delivery: safely crossing the blood-brain barrier. Drug Discov Today Technol. 2012;9(2):e71\u2013174. https:\/\/doi.org\/10.1016\/j.ddtec.2011.12.002.","journal-title":"Drug Discov Today Technol"},{"issue":"suppl 5","key":"1775_CR15","doi-asserted-by":"publisher","first-page":"v92","DOI":"10.1093\/neuonc\/nou255.58","volume":"16","author":"AT Ashizawa","year":"2014","unstructured":"Ashizawa AT, Steindler D. Et-61 * Novel Lipid Nanoparticles for the Delivery of Nucleic Acids to Glioblastoma. Neuro Oncol. 2014;16(suppl 5):v92\u2013v92. https:\/\/doi.org\/10.1093\/neuonc\/nou255.58.","journal-title":"Neuro Oncol"},{"issue":"12","key":"1775_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081043","volume":"8","author":"R Gromnicova","year":"2013","unstructured":"Gromnicova R, et al. Glucose-coated gold nanoparticles transfer across human brain endothelium and enter astrocytes in vitro. PLoS ONE. 2013;8(12): e81043. https:\/\/doi.org\/10.1371\/journal.pone.0081043.","journal-title":"PLoS ONE"},{"issue":"12","key":"1775_CR17","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2217\/nnm-2017-0023","volume":"12","author":"MJ Gomes","year":"2017","unstructured":"Gomes MJ, et al. Delivery of siRNA silencing P-gp in peptide-functionalized nanoparticles causes efflux modulation at the blood-brain barrier. Nanomedicine (Lond). 2017;12(12):1385\u201399. https:\/\/doi.org\/10.2217\/nnm-2017-0023.","journal-title":"Nanomedicine (Lond)"},{"issue":"12","key":"1775_CR18","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/cells13120998","volume":"13","author":"E ter Linden","year":"2024","unstructured":"ter Linden E, et al. Overcoming Barriers in Glioblastoma\u2014Advances in Drug Delivery Strategies. Cells. 2024;13(12):998. https:\/\/doi.org\/10.3390\/cells13120998.","journal-title":"Cells"},{"key":"1775_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.addr.2021.01.012","volume":"171","author":"TI Janjua","year":"2021","unstructured":"Janjua TI, et al. Frontiers in the treatment of glioblastoma: Past, present and emerging. Adv Drug Deliv Rev. 2021;171:108\u201338. https:\/\/doi.org\/10.1016\/j.addr.2021.01.012.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"1775_CR20","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.1038\/s41467-020-19225-7","volume":"11","author":"JV Gregory","year":"2020","unstructured":"Gregory JV, et al. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nat Commun. 2020;11(1):5687. https:\/\/doi.org\/10.1038\/s41467-020-19225-7.","journal-title":"Nat Commun"},{"issue":"26","key":"1775_CR21","doi-asserted-by":"publisher","first-page":"8752","DOI":"10.1002\/anie.201902612","volume":"58","author":"Z He","year":"2019","unstructured":"He Z, et al. A Catalase-Like Metal-Organic Framework Nanohybrid for O(2) -Evolving Synergistic Chemoradiotherapy. Angew Chem Int Ed Engl. 2019;58(26):8752\u20136. https:\/\/doi.org\/10.1002\/anie.201902612.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"16","key":"1775_CR22","doi-asserted-by":"publisher","first-page":"7600","DOI":"10.1039\/c9nr01789e","volume":"11","author":"H Zhang","year":"2019","unstructured":"Zhang H, et al. Second near-infrared photodynamic therapy and chemotherapy of orthotopic malignant glioblastoma with ultra-small Cu(2\u2013x)Se nanoparticles. Nanoscale. 2019;11(16):7600\u20138. https:\/\/doi.org\/10.1039\/c9nr01789e.","journal-title":"Nanoscale"},{"issue":"4","key":"1775_CR23","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1021\/acsnano.8b00999","volume":"12","author":"P Zhu","year":"2018","unstructured":"Zhu P, Chen Y, Shi J. Nanoenzyme-Augmented Cancer Sonodynamic Therapy by Catalytic Tumor Oxygenation. ACS Nano. 2018;12(4):3780\u201395. https:\/\/doi.org\/10.1021\/acsnano.8b00999.","journal-title":"ACS Nano"},{"issue":"16","key":"1775_CR24","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1039\/c6nr08172j","volume":"9","author":"SR Bhattarai","year":"2017","unstructured":"Bhattarai SR, et al. Gold nanotriangles: scale up and X-ray radiosensitization effects in mice. Nanoscale. 2017;9(16):5085\u201393. https:\/\/doi.org\/10.1039\/c6nr08172j.","journal-title":"Nanoscale"},{"issue":"2","key":"1775_CR25","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1021\/acsnano.8b06842","volume":"13","author":"P Kadiyala","year":"2019","unstructured":"Kadiyala P, et al. High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme. ACS Nano. 2019;13(2):1365\u201384. https:\/\/doi.org\/10.1021\/acsnano.8b06842.","journal-title":"ACS Nano"},{"issue":"11","key":"1775_CR26","doi-asserted-by":"publisher","first-page":"8276","DOI":"10.1166\/jnn.2012.6626","volume":"12","author":"H Jiang","year":"2012","unstructured":"Jiang H, et al. Silver nanocrystals mediated combination therapy of radiation with magnetic hyperthermia on glioma cells. J Nanosci Nanotechnol. 2012;12(11):8276\u201381. https:\/\/doi.org\/10.1166\/jnn.2012.6626.","journal-title":"J Nanosci Nanotechnol"},{"key":"1775_CR27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.addr.2019.01.005","volume":"138","author":"SM Dadfar","year":"2019","unstructured":"Dadfar SM, et al. Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019;138:302\u201325. https:\/\/doi.org\/10.1016\/j.addr.2019.01.005.","journal-title":"Adv Drug Deliv Rev"},{"issue":"18","key":"1775_CR28","doi-asserted-by":"publisher","first-page":"20271","DOI":"10.1021\/acsami.0c03748","volume":"12","author":"Z Gao","year":"2020","unstructured":"Gao Z, et al. Polypeptide-Based Theranostics with Tumor-Microenvironment-Activatable Cascade Reaction for Chemo-ferroptosis Combination Therapy. ACS Appl Mater Interfaces. 2020;12(18):20271\u201380. https:\/\/doi.org\/10.1021\/acsami.0c03748.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"584","key":"1775_CR29","doi-asserted-by":"publisher","first-page":"eabb3945","DOI":"10.1126\/scitranslmed.abb3945","volume":"13","author":"P Kumthekar","year":"2021","unstructured":"Kumthekar P, et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med. 2021;13(584):eabb3945. https:\/\/doi.org\/10.1126\/scitranslmed.abb3945.","journal-title":"Sci Transl Med"},{"key":"1775_CR30","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/1471-2407-9-308","volume":"9","author":"CP Beier","year":"2009","unstructured":"Beier CP, et al. RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma\u2013a phase II study. BMC Cancer. 2009;9:308. https:\/\/doi.org\/10.1186\/1471-2407-9-308.","journal-title":"BMC Cancer"},{"issue":"2","key":"1775_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11060-010-0389-0","volume":"103","author":"K Maier-Hauff","year":"2011","unstructured":"Maier-Hauff K, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103(2):317\u201324. https:\/\/doi.org\/10.1007\/s11060-010-0389-0.","journal-title":"J Neurooncol"},{"issue":"6","key":"1775_CR32","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/biom12060784","volume":"12","author":"F Rodr\u00edguez","year":"2022","unstructured":"Rodr\u00edguez F, et al. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules. 2022;12(6):784. https:\/\/doi.org\/10.3390\/biom12060784.","journal-title":"Biomolecules"},{"issue":"4","key":"1775_CR33","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3109\/10717544.2015.1064186","volume":"23","author":"S Song","year":"2016","unstructured":"Song S, et al. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Deliv. 2016;23(4):1404\u20138. https:\/\/doi.org\/10.3109\/10717544.2015.1064186.","journal-title":"Drug Deliv"},{"issue":"4","key":"1775_CR34","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3109\/10717544.2015.1049719","volume":"23","author":"Y Chen","year":"2016","unstructured":"Chen Y, et al. Nanostructured lipid carriers enhance the bioavailability and brain cancer inhibitory efficacy of curcumin both in vitro and in vivo. Drug Deliv. 2016;23(4):1383\u201392. https:\/\/doi.org\/10.3109\/10717544.2015.1049719.","journal-title":"Drug Deliv"},{"issue":"3","key":"1775_CR35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.34172\/apb.2023.056","volume":"13","author":"S Khan","year":"2023","unstructured":"Khan S, Sharma A, Jain V. An Overview of Nanostructured Lipid Carriers and its Application in Drug Delivery through Different Routes. Adv Pharm Bull. 2023;13(3):446\u201360. https:\/\/doi.org\/10.34172\/apb.2023.056.","journal-title":"Adv Pharm Bull"},{"issue":"4","key":"1775_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/pharmaceutics13040437","volume":"13","author":"P Mura","year":"2021","unstructured":"Mura P, et al. Evaluation and Comparison of Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) as Vectors to Develop Hydrochlorothiazide Effective and Safe Pediatric Oral Liquid Formulations. Pharmaceutics. 2021;13(4):437. https:\/\/doi.org\/10.3390\/pharmaceutics13040437.","journal-title":"Pharmaceutics"},{"key":"1775_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2020.111774","volume":"121","author":"T Zwain","year":"2021","unstructured":"Zwain T, et al. Tailoring functional nanostructured lipid carriers for glioblastoma treatment with enhanced permeability through in-vitro 3D BBB\/BBTB models. Mater Sci Eng C Mater Biol Appl. 2021;121: 111774. https:\/\/doi.org\/10.1016\/j.msec.2020.111774.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"1775_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121682","volume":"618","author":"LD Di Filippo","year":"2022","unstructured":"Di Filippo LD, et al. Glioblastoma multiforme targeted delivery of docetaxel using bevacizumab-modified nanostructured lipid carriers impair in vitro cell growth and in vivo tumor progression. Int J Pharm. 2022;618: 121682. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121682.","journal-title":"Int J Pharm"},{"issue":"2","key":"1775_CR39","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605X\/abdc97","volume":"16","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Sun T, Jiang C. Recent advances on drug delivery nanocarriers for cerebral disorders. Biomed Mater. 2021;16(2): 024104. https:\/\/doi.org\/10.1088\/1748-605X\/abdc97.","journal-title":"Biomed Mater"},{"issue":"7","key":"1775_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s10856-021-06538-2","volume":"32","author":"AS Shirazi","year":"2021","unstructured":"Shirazi AS, et al. SN38 loaded nanostructured lipid carriers (NLCs); preparation and in vitro evaluations against glioblastoma. J Mater Sci Mater Med. 2021;32(7):78. https:\/\/doi.org\/10.1007\/s10856-021-06538-2.","journal-title":"J Mater Sci Mater Med"},{"issue":"2","key":"1775_CR41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11060-004-2751-6","volume":"70","author":"T Demuth","year":"2004","unstructured":"Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol. 2004;70(2):217\u201328. https:\/\/doi.org\/10.1007\/s11060-004-2751-6.","journal-title":"J Neurooncol"},{"key":"1775_CR42","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2147\/CMAR.S186142","volume":"11","author":"A Hatoum","year":"2019","unstructured":"Hatoum A, Mohammed R, Zakieh O. The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix. Cancer Manag Res. 2019;11:1843\u201355. https:\/\/doi.org\/10.2147\/CMAR.S186142.","journal-title":"Cancer Manag Res"},{"issue":"21","key":"1775_CR43","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1111\/febs.12393","volume":"280","author":"HK Gan","year":"2013","unstructured":"Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 2013;280(21):5350\u201370. https:\/\/doi.org\/10.1111\/febs.12393.","journal-title":"FEBS J"},{"issue":"5","key":"1775_CR44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","volume":"9","author":"P Wee","year":"2017","unstructured":"Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers. 2017;9(5):52. https:\/\/doi.org\/10.3390\/cancers9050052.","journal-title":"Cancers"},{"issue":"1","key":"1775_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2015.03.015","volume":"362","author":"I Paw","year":"2015","unstructured":"Paw I, et al. Mechanisms regulating glioma invasion. Cancer Lett. 2015;362(1):1\u20137. https:\/\/doi.org\/10.1016\/j.canlet.2015.03.015.","journal-title":"Cancer Lett"},{"issue":"1","key":"1775_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5301\/ijbm.5000301","volume":"33","author":"FS Saadeh","year":"2018","unstructured":"Saadeh FS, Mahfouz R, Assi HI. EGFR as a clinical marker in glioblastomas and other gliomas. Int J Biol Markers. 2018;33(1):22\u201332. https:\/\/doi.org\/10.5301\/ijbm.5000301.","journal-title":"Int J Biol Markers"},{"key":"1775_CR47","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2147\/OTT.S155160","volume":"11","author":"J Li","year":"2018","unstructured":"Li J, et al. Prognostic significance of epidermal growth factor receptor expression in glioma patients. Onco Targets Ther. 2018;11:731\u201342. https:\/\/doi.org\/10.2147\/OTT.S155160.","journal-title":"Onco Targets Ther"},{"key":"1775_CR48","doi-asserted-by":"publisher","first-page":"1092587","DOI":"10.1155\/2019\/1092587","volume":"2019","author":"A Rutkowska","year":"2019","unstructured":"Rutkowska A, et al. EGFR(vIII): An Oncogene with Ambiguous Role. J Oncol. 2019;2019:1092587. https:\/\/doi.org\/10.1155\/2019\/1092587.","journal-title":"J Oncol"},{"issue":"16","key":"1775_CR49","doi-asserted-by":"publisher","first-page":"8835","DOI":"10.3390\/ijms23168835","volume":"23","author":"H Sareen","year":"2022","unstructured":"Sareen H, et al. Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2022;23(16):8835. https:\/\/doi.org\/10.3390\/ijms23168835.","journal-title":"Int J Mol Sci"},{"key":"1775_CR50","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ijbiomac.2014.06.009","volume":"69","author":"S Maya","year":"2014","unstructured":"Maya S, et al. Chitosan cross-linked docetaxel loaded EGF receptor targeted nanoparticles for lung cancer cells. Int J Biol Macromol. 2014;69:532\u201341. https:\/\/doi.org\/10.1016\/j.ijbiomac.2014.06.009.","journal-title":"Int J Biol Macromol"},{"issue":"17","key":"1775_CR51","doi-asserted-by":"publisher","first-page":"24752","DOI":"10.18632\/oncotarget.8407","volume":"7","author":"W Xu","year":"2016","unstructured":"Xu W, et al. Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo. Oncotarget. 2016;7(17):24752\u201365. https:\/\/doi.org\/10.18632\/oncotarget.8407.","journal-title":"Oncotarget"},{"issue":"3","key":"1775_CR52","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1124\/pharmrev.121.000349","volume":"74","author":"LGN de Almeida","year":"2022","unstructured":"de Almeida LGN, et al. Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology. Pharmacol Rev. 2022;74(3):714\u201370. https:\/\/doi.org\/10.1124\/pharmrev.121.000349.","journal-title":"Pharmacol Rev"},{"issue":"5","key":"1775_CR53","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5306\/wjco.v3.i5.67","volume":"3","author":"C Hagemann","year":"2012","unstructured":"Hagemann C, et al. A complete compilation of matrix metalloproteinase expression in human malignant gliomas. World J Clin Oncol. 2012;3(5):67\u201379. https:\/\/doi.org\/10.5306\/wjco.v3.i5.67.","journal-title":"World J Clin Oncol"},{"issue":"7","key":"1775_CR54","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc1121","volume":"3","author":"JS Rao","year":"2003","unstructured":"Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003;3(7):489\u2013501. https:\/\/doi.org\/10.1038\/nrc1121.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1775_CR55","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3892\/ol.2017.5567","volume":"13","author":"Q Xue","year":"2017","unstructured":"Xue Q, et al. High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates. Oncol Lett. 2017;13(3):1325\u201330. https:\/\/doi.org\/10.3892\/ol.2017.5567.","journal-title":"Oncol Lett"},{"issue":"2","key":"1775_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172234","volume":"12","author":"RK Ramachandran","year":"2017","unstructured":"Ramachandran RK, et al. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas. PLoS ONE. 2017;12(2): e0172234. https:\/\/doi.org\/10.1371\/journal.pone.0172234.","journal-title":"PLoS ONE"},{"issue":"5","key":"1775_CR57","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/path.5225","volume":"247","author":"GA Conlon","year":"2019","unstructured":"Conlon GA, Murray GI. Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 2019;247(5):629\u201340. https:\/\/doi.org\/10.1002\/path.5225.","journal-title":"J Pathol"},{"issue":"8","key":"1775_CR58","doi-asserted-by":"publisher","first-page":"7047","DOI":"10.3390\/ijms24087047","volume":"24","author":"JI Erices","year":"2023","unstructured":"Erices JI, et al. Glioblastoma Microenvironment and Invasiveness: New Insights and Therapeutic Targets. Int J Mol Sci. 2023;24(8):7047.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1775_CR59","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ijc.11313","volume":"106","author":"C Munaut","year":"2003","unstructured":"Munaut C, et al. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer J Int du Cancer. 2003;106(6):848\u201355. https:\/\/doi.org\/10.1002\/ijc.11313.","journal-title":"Int J Cancer. J Int du Cancer"},{"issue":"9","key":"1775_CR60","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.3390\/cancers12092456","volume":"12","author":"I Thome","year":"2020","unstructured":"Thome I, et al. Neoplastic Cells are the Major Source of MT-MMPs in IDH1-Mutant Glioma, Thus Enhancing Tumor-Cell Intrinsic Brain Infiltration. Cancers. 2020;12(9):2456. https:\/\/doi.org\/10.3390\/cancers12092456.","journal-title":"Cancers."},{"issue":"9","key":"1775_CR61","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1158\/1535-7163.MCT-17-0022","volume":"16","author":"S Mohanty","year":"2017","unstructured":"Mohanty S, et al. A Novel Theranostic Strategy for MMP-14-Expressing Glioblastomas Impacts Survival. Mol Cancer Ther. 2017;16(9):1909\u201321. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0022.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1775_CR62","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s00259-019-04607-x","volume":"47","author":"BB Kasten","year":"2020","unstructured":"Kasten BB, et al. Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models. Eur J Nucl Med Mol Imaging. 2020;47(6):1412\u201326. https:\/\/doi.org\/10.1007\/s00259-019-04607-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1775_CR63","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11060-005-9098-5","volume":"78","author":"VA Levin","year":"2006","unstructured":"Levin VA, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol. 2006;78(3):295\u2013302. https:\/\/doi.org\/10.1007\/s11060-005-9098-5.","journal-title":"J Neurooncol"},{"issue":"5","key":"1775_CR64","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.2002.20.5.1383","volume":"20","author":"MD Groves","year":"2002","unstructured":"Groves MD, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002;20(5):1383\u20138. https:\/\/doi.org\/10.1200\/JCO.2002.20.5.1383.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1775_CR65","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s0748-7983(97)93077-8","volume":"23","author":"SL Parsons","year":"1997","unstructured":"Parsons SL, Watson SA, Steele RJ. Phase I\/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol. 1997;23(6):526\u201331. https:\/\/doi.org\/10.1016\/s0748-7983(97)93077-8.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"1775_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02990939","volume":"14","author":"PD Brown","year":"1997","unstructured":"Brown PD. Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol. 1997;14(1):1\u201310. https:\/\/doi.org\/10.1007\/BF02990939.","journal-title":"Med Oncol"},{"issue":"4","key":"1775_CR67","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/1568009054064615","volume":"5","author":"F Mannello","year":"2005","unstructured":"Mannello F, Tonti G, Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets. 2005;5(4):285\u201398. https:\/\/doi.org\/10.2174\/1568009054064615.","journal-title":"Curr Cancer Drug Targets"},{"issue":"18","key":"1775_CR68","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.2174\/0929867325666180514111500","volume":"26","author":"A Boguszewska-Czubara","year":"2019","unstructured":"Boguszewska-Czubara A, et al. Perspectives and New Aspects of Metalloproteinases\u2019 Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine. Curr Med Chem. 2019;26(18):3208\u201324. https:\/\/doi.org\/10.2174\/0929867325666180514111500.","journal-title":"Curr Med Chem"},{"issue":"1","key":"1775_CR69","doi-asserted-by":"publisher","first-page":"21314","DOI":"10.1038\/s41598-020-78341-y","volume":"10","author":"B Pijet","year":"2020","unstructured":"Pijet B, et al. The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus. Sci Rep. 2020;10(1):21314. https:\/\/doi.org\/10.1038\/s41598-020-78341-y.","journal-title":"Sci Rep"},{"issue":"2","key":"1775_CR70","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.bbcan.2011.12.001","volume":"1825","author":"R Mentlein","year":"2012","unstructured":"Mentlein R, Hattermann K, Held-Feindt J. Lost in disruption: role of proteases in glioma invasion and progression. Biochem Biophys Acta. 2012;1825(2):178\u201385. https:\/\/doi.org\/10.1016\/j.bbcan.2011.12.001.","journal-title":"Biochem Biophys Acta"},{"issue":"1","key":"1775_CR71","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.gendis.2014.12.002","volume":"2","author":"J Cathcart","year":"2015","unstructured":"Cathcart J, Pulkoski-Gross A, Cao J. Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old Ideas. Genes Dis. 2015;2(1):26\u201334. https:\/\/doi.org\/10.1016\/j.gendis.2014.12.002.","journal-title":"Genes Dis"},{"issue":"2","key":"1775_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188428","volume":"1874","author":"A Quesnel","year":"2020","unstructured":"Quesnel A, Karagiannis GS, Filippou PS. Extracellular proteolysis in glioblastoma progression and therapeutics. Biochim Biophys Acta Rev Cancer. 2020;1874(2): 188428. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188428.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"18","key":"1775_CR73","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.7150\/thno.19403","volume":"7","author":"D Sehedic","year":"2017","unstructured":"Sehedic D, et al. Locoregional Confinement and Major Clinical Benefit of (188)Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma. Theranostics. 2017;7(18):4517\u201336. https:\/\/doi.org\/10.7150\/thno.19403.","journal-title":"Theranostics"},{"issue":"22","key":"1775_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202300029","volume":"19","author":"C Martins","year":"2023","unstructured":"Martins C, et al. Stimuli-Responsive Multifunctional Nanomedicine for Enhanced Glioblastoma Chemotherapy Augments Multistage Blood-to-Brain Trafficking and Tumor Targeting. Small. 2023;19(22): e2300029. https:\/\/doi.org\/10.1002\/smll.202300029.","journal-title":"Small"},{"issue":"1","key":"1775_CR75","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40199-019-00324-w","volume":"28","author":"M Esfandyari-Manesh","year":"2020","unstructured":"Esfandyari-Manesh M, et al. S2P peptide-conjugated PLGA-Maleimide-PEG nanoparticles containing Imatinib for targeting drug delivery to atherosclerotic plaques. Daru. 2020;28(1):131\u20138. https:\/\/doi.org\/10.1007\/s40199-019-00324-w.","journal-title":"Daru"},{"key":"1775_CR76","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.2147\/IJN.S202424","volume":"14","author":"D Kebebe","year":"2019","unstructured":"Kebebe D, et al. Dimeric c(RGD) peptide conjugated nanostructured lipid carriers for efficient delivery of Gambogic acid to breast cancer. Int J Nanomed. 2019;14:6179\u201395. https:\/\/doi.org\/10.2147\/IJN.S202424.","journal-title":"Int J Nanomed"},{"issue":"1","key":"1775_CR77","doi-asserted-by":"publisher","first-page":"92","DOI":"10.7150\/thno.21074","volume":"8","author":"L Gao","year":"2018","unstructured":"Gao L, et al. Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T(1)-T(2) Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics. Theranostics. 2018;8(1):92\u2013108. https:\/\/doi.org\/10.7150\/thno.21074.","journal-title":"Theranostics"},{"issue":"1","key":"1775_CR78","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","volume":"150","author":"PK Smith","year":"1985","unstructured":"Smith PK, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150(1):76\u201385. https:\/\/doi.org\/10.1016\/0003-2697(85)90442-7.","journal-title":"Anal Biochem"},{"issue":"1\u20132","key":"1775_CR79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijpharm.2015.07.013","volume":"492","author":"M Ferreira","year":"2015","unstructured":"Ferreira M, et al. Optimization of nanostructured lipid carriers loaded with methotrexate: A tool for inflammatory and cancer therapy. Int J Pharm. 2015;492(1\u20132):65\u201372. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.07.013.","journal-title":"Int J Pharm"},{"key":"1775_CR80","doi-asserted-by":"publisher","unstructured":"Udenfriend S, et al. Fluorescamine: A Reagent for Assay of Amino Acids, Peptides, Proteins, and Primary Amines in the Picomole Range. Science (New York, N.Y.), 1972. 178(4063): p. 871\u2013872. https:\/\/doi.org\/10.1126\/science.178.4063.871","DOI":"10.1126\/science.178.4063.871"},{"issue":"1","key":"1775_CR81","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1038\/s41467-022-29693-8","volume":"13","author":"Z Cao","year":"2022","unstructured":"Cao Z, et al. Bioorthogonal in situ assembly of nanomedicines as drug depots for extracellular drug delivery. Nat Commun. 2022;13(1):2038. https:\/\/doi.org\/10.1038\/s41467-022-29693-8.","journal-title":"Nat Commun"},{"issue":"2","key":"1775_CR82","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/0003-2697(92)90248-6","volume":"204","author":"RE Morton","year":"1992","unstructured":"Morton RE, Evans TA. Modification of the bicinchoninic acid protein assay to eliminate lipid interference in determining lipoprotein protein content. Anal Biochem. 1992;204(2):332\u20134. https:\/\/doi.org\/10.1016\/0003-2697(92)90248-6.","journal-title":"Anal Biochem"},{"issue":"14","key":"1775_CR83","doi-asserted-by":"publisher","first-page":"11285","DOI":"10.3390\/ijms241411285","volume":"24","author":"J Peixoto","year":"2023","unstructured":"Peixoto J, et al. Using a Dual CRISPR\/Cas9 Approach to Gain Insight into the Role of LRP1B in Glioblastoma. Int J Mol Sci. 2023;24(14):11285. https:\/\/doi.org\/10.3390\/ijms241411285.","journal-title":"Int J Mol Sci"},{"issue":"32","key":"1775_CR84","doi-asserted-by":"publisher","first-page":"52003","DOI":"10.18632\/oncotarget.10468","volume":"7","author":"LB Ferreira","year":"2016","unstructured":"Ferreira LB, et al. Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. Oncotarget. 2016;7(32):52003\u201316. https:\/\/doi.org\/10.18632\/oncotarget.10468.","journal-title":"Oncotarget"},{"issue":"16","key":"1775_CR85","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1038\/onc.2013.154","volume":"33","author":"AP Cardoso","year":"2014","unstructured":"Cardoso AP, et al. Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y1086, c-Src, Erk1\/2 and Akt phosphorylation and smallGTPase activity. Oncogene. 2014;33(16):2123\u201333. https:\/\/doi.org\/10.1038\/onc.2013.154.","journal-title":"Oncogene"},{"key":"1775_CR86","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jconrel.2018.03.002","volume":"282","author":"L Martinez-Jothar","year":"2018","unstructured":"Martinez-Jothar L, et al. Insights into maleimide-thiol conjugation chemistry: Conditions for efficient surface functionalization of nanoparticles for receptor targeting. J Control Release. 2018;282:101\u20139. https:\/\/doi.org\/10.1016\/j.jconrel.2018.03.002.","journal-title":"J Control Release"},{"issue":"8","key":"1775_CR87","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00775-014-1195-5","volume":"19","author":"A Van Koninckxloo","year":"2014","unstructured":"Van Koninckxloo A, et al. NMR chemical shift study of the interaction of selected peptides with liposomal and micellar models of apoptotic cells. J Biol Inorg Chem. 2014;19(8):1367\u201376. https:\/\/doi.org\/10.1007\/s00775-014-1195-5.","journal-title":"J Biol Inorg Chem"},{"issue":"6","key":"1775_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202000048","volume":"20","author":"S Kumar","year":"2020","unstructured":"Kumar S, Hause G, Binder WH. Thio-Bromo \u201cClick\u201d Reaction Derived Polymer-Peptide Conjugates for Their Self-Assembled Fibrillar Nanostructures. Macromol Biosci. 2020;20(6): e2000048. https:\/\/doi.org\/10.1002\/mabi.202000048.","journal-title":"Macromol Biosci"},{"key":"1775_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2021.118226","volume":"267","author":"F Gurer","year":"2021","unstructured":"Gurer F, et al. Water-based carbodiimide mediated synthesis of polysaccharide-amino acid conjugates: Deprotection, charge and structural analysis. Carbohyd Polym. 2021;267: 118226. https:\/\/doi.org\/10.1016\/j.carbpol.2021.118226.","journal-title":"Carbohyd Polym"},{"issue":"1","key":"1775_CR90","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13036-019-0191-2","volume":"13","author":"MP Wickramathilaka","year":"2019","unstructured":"Wickramathilaka MP, Tao BY. Characterization of covalent crosslinking strategies for synthesizing DNA-based bioconjugates. J Biol Eng. 2019;13(1):63. https:\/\/doi.org\/10.1186\/s13036-019-0191-2.","journal-title":"J Biol Eng"},{"issue":"2","key":"1775_CR91","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","volume":"10","author":"M Danaei","year":"2018","unstructured":"Danaei M, et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018;10(2):57. https:\/\/doi.org\/10.3390\/pharmaceutics10020057.","journal-title":"Pharmaceutics"},{"issue":"46","key":"1775_CR92","doi-asserted-by":"publisher","first-page":"1801362","DOI":"10.1002\/adma.201801362","volume":"30","author":"D Furtado","year":"2018","unstructured":"Furtado D, et al. Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Adv Mater. 2018;30(46):1801362. https:\/\/doi.org\/10.1002\/adma.201801362.","journal-title":"Adv Mater"},{"issue":"3","key":"1775_CR93","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1021\/ar200113c","volume":"45","author":"TL Doane","year":"2012","unstructured":"Doane TL, et al. Nanoparticle zeta -potentials. Acc Chem Res. 2012;45(3):317\u201326. https:\/\/doi.org\/10.1021\/ar200113c.","journal-title":"Acc Chem Res"},{"issue":"9","key":"1775_CR94","doi-asserted-by":"publisher","first-page":"6304","DOI":"10.1039\/d2ra07005g","volume":"13","author":"M Chang","year":"2023","unstructured":"Chang M. Matrix metalloproteinase profiling and their roles in disease. RSC Adv. 2023;13(9):6304\u201316. https:\/\/doi.org\/10.1039\/d2ra07005g.","journal-title":"RSC Adv"},{"issue":"8","key":"1775_CR95","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/bios12080660","volume":"12","author":"A Anchan","year":"2022","unstructured":"Anchan A, et al. Melanoma Mediated Disruption of Brain Endothelial Barrier Integrity Is Not Prevented by the Inhibition of Matrix Metalloproteinases and Proteases. Biosensors (Basel). 2022;12(8):660. https:\/\/doi.org\/10.3390\/bios12080660.","journal-title":"Biosensors (Basel)"},{"issue":"11","key":"1775_CR96","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1161\/CIRCRESAHA.115.307207","volume":"117","author":"N Nosoudi","year":"2015","unstructured":"Nosoudi N, et al. Prevention of abdominal aortic aneurysm progression by targeted inhibition of matrix metalloproteinase activity with batimastat-loaded nanoparticles. Circ Res. 2015;117(11):e80\u20139. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.307207.","journal-title":"Circ Res"},{"issue":"12","key":"1775_CR97","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3390\/pharmaceutics13121990","volume":"13","author":"K Zhang","year":"2021","unstructured":"Zhang K, et al. Dual Targeting of Cancer Cells and MMPs with Self-Assembly Hybrid Nanoparticles for Combination Therapy in Combating Cancer. Pharmaceutics. 2021;13(12):1990. https:\/\/doi.org\/10.3390\/pharmaceutics13121990.","journal-title":"Pharmaceutics"},{"key":"1775_CR98","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jconrel.2020.01.035","volume":"320","author":"AC Marques","year":"2020","unstructured":"Marques AC, et al. Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies. J Control Release. 2020;320:180\u2013200. https:\/\/doi.org\/10.1016\/j.jconrel.2020.01.035.","journal-title":"J Control Release"},{"key":"1775_CR99","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.2147\/ijn.S67770","volume":"9","author":"Y Han","year":"2014","unstructured":"Han Y, et al. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin. Int J Nanomed. 2014;9:4107\u201316. https:\/\/doi.org\/10.2147\/ijn.S67770.","journal-title":"Int J Nanomed"},{"key":"1775_CR100","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jconrel.2023.04.034","volume":"358","author":"RP Moura","year":"2023","unstructured":"Moura RP, et al. Functionalized retinoic acid lipid nanocapsules promotes a two-front attack on inflammation and lack of demyelination on neurodegenerative disorders. J Control Release. 2023;358:43\u201358. https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.034.","journal-title":"J Control Release"},{"issue":"2","key":"1775_CR101","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3109\/17435390.2013.773465","volume":"8","author":"W-S Cho","year":"2014","unstructured":"Cho W-S, et al. Surface functionalization affects the zeta potential, coronal stability and membranolytic activity of polymeric nanoparticles. Nanotoxicology. 2014;8(2):202\u201311. https:\/\/doi.org\/10.3109\/17435390.2013.773465.","journal-title":"Nanotoxicology"},{"issue":"5","key":"1775_CR102","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3109\/10717544.2015.1099058","volume":"23","author":"J Du","year":"2016","unstructured":"Du J, Li L. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers? Drug Delivery. 2016;23(5):1799\u2013809. https:\/\/doi.org\/10.3109\/10717544.2015.1099058.","journal-title":"Drug Delivery"},{"issue":"1","key":"1775_CR103","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/pharmaceutics14010185","volume":"14","author":"MI Teixeira","year":"2022","unstructured":"Teixeira MI, et al. Formulation, Characterization, and Cytotoxicity Evaluation of Lactoferrin Functionalized Lipid Nanoparticles for Riluzole Delivery to the Brain. Pharmaceutics. 2022;14(1):185. https:\/\/doi.org\/10.3390\/pharmaceutics14010185.","journal-title":"Pharmaceutics"},{"issue":"Suppl 1","key":"1775_CR104","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/s0169-409x(02)00118-7","volume":"54","author":"RH Muller","year":"2002","unstructured":"Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(Suppl 1):S131\u201355. https:\/\/doi.org\/10.1016\/s0169-409x(02)00118-7.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"1775_CR105","doi-asserted-by":"publisher","first-page":"143","DOI":"10.15171\/apb.2016.021","volume":"6","author":"L Azhar Shekoufeh Bahari","year":"2016","unstructured":"Azhar Shekoufeh Bahari L, Hamishehkar H. The Impact of Variables on Particle Size of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers; A Comparative Literature Review. Adv Pharm Bull. 2016;6(2):143\u201351. https:\/\/doi.org\/10.15171\/apb.2016.021.","journal-title":"Adv Pharm Bull"},{"issue":"1","key":"1775_CR106","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/2045-8118-10-16","volume":"10","author":"B Weksler","year":"2013","unstructured":"Weksler B, Romero IA, Couraud P-O. The hCMEC\/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS. 2013;10(1):16. https:\/\/doi.org\/10.1186\/2045-8118-10-16.","journal-title":"Fluids Barriers CNS"},{"issue":"3","key":"1775_CR107","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.3390\/ijms24032710","volume":"24","author":"B Chaulagain","year":"2023","unstructured":"Chaulagain B, et al. Experimental Models of In Vitro Blood-Brain Barrier for CNS Drug Delivery: An Evolutionary Perspective. Int J Mol Sci. 2023;24(3):2710. https:\/\/doi.org\/10.3390\/ijms24032710.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"1775_CR108","doi-asserted-by":"publisher","first-page":"8818","DOI":"10.3390\/molecules27248818","volume":"27","author":"DPC de Barros","year":"2022","unstructured":"de Barros DPC, et al. Design of Quercetin-Loaded Natural Oil-Based Nanostructured Lipid Carriers for the Treatment of Bacterial Skin Infections. Molecules (Basel, Switzerland). 2022;27(24):8818. https:\/\/doi.org\/10.3390\/molecules27248818.","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"10","key":"1775_CR109","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3390\/pharmaceutics14102237","volume":"14","author":"MS Thomsen","year":"2022","unstructured":"Thomsen MS, et al. Blood-Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles. Pharmaceutics. 2022;14(10):2237. https:\/\/doi.org\/10.3390\/pharmaceutics14102237.","journal-title":"Pharmaceutics"},{"issue":"46","key":"1775_CR110","doi-asserted-by":"publisher","first-page":"10772","DOI":"10.1039\/C9SC04024B","volume":"10","author":"R Beard","year":"2019","unstructured":"Beard R, et al. Chemical biology tools for probing transcytosis at the blood\u2013brain barrier. Chem Sci. 2019;10(46):10772\u20138. https:\/\/doi.org\/10.1039\/C9SC04024B.","journal-title":"Chem Sci"},{"key":"1775_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2019.101665","volume":"181","author":"KB Johnsen","year":"2019","unstructured":"Johnsen KB, et al. Targeting the transferrin receptor for brain drug delivery. Prog Neurobiol. 2019;181: 101665. https:\/\/doi.org\/10.1016\/j.pneurobio.2019.101665.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"1775_CR112","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11481-016-9685-6","volume":"12","author":"MJ Gomes","year":"2017","unstructured":"Gomes MJ, et al. Tailoring Lipid and Polymeric Nanoparticles as siRNA Carriers towards the Blood-Brain Barrier - from Targeting to Safe Administration. J Neuroimmune Pharmacol. 2017;12(1):107\u201319. https:\/\/doi.org\/10.1007\/s11481-016-9685-6.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"2","key":"1775_CR113","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/BST20180444","volume":"47","author":"SL Perrin","year":"2019","unstructured":"Perrin SL, et al. Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments. Biochem Soc Trans. 2019;47(2):625\u201338. https:\/\/doi.org\/10.1042\/BST20180444.","journal-title":"Biochem Soc Trans"},{"key":"1775_CR114","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/1756-0500-3-293","volume":"3","author":"C Hagemann","year":"2010","unstructured":"Hagemann C, et al. Comparative expression pattern of Matrix-Metalloproteinases in human glioblastoma cell-lines and primary cultures. BMC Res Notes. 2010;3:293. https:\/\/doi.org\/10.1186\/1756-0500-3-293.","journal-title":"BMC Res Notes"},{"issue":"6","key":"1775_CR115","doi-asserted-by":"publisher","first-page":"894","DOI":"10.5137\/1019-5149.JTN.17746-16.1","volume":"27","author":"H Li","year":"2017","unstructured":"Li H, et al. Differences in Protein Expression between the U251 and U87 Cell Lines. Turk Neurosurg. 2017;27(6):894\u2013903. https:\/\/doi.org\/10.5137\/1019-5149.JTN.17746-16.1.","journal-title":"Turk Neurosurg"},{"issue":"38","key":"1775_CR116","doi-asserted-by":"publisher","first-page":"40998","DOI":"10.18632\/oncotarget.5701","volume":"6","author":"H Motaln","year":"2015","unstructured":"Motaln H, et al. Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance. Oncotarget. 2015;6(38):40998\u20131017. https:\/\/doi.org\/10.18632\/oncotarget.5701.","journal-title":"Oncotarget"},{"issue":"6","key":"1775_CR117","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1021\/acsbiomaterials.6b00052","volume":"2","author":"BN Eldridge","year":"2016","unstructured":"Eldridge BN, et al. Photothermal therapy of glioblastoma multiforme using multiwalled carbon nanotubes optimized for diffusion in extracellular space. ACS Biomater Sci Eng. 2016;2(6):963\u201376. https:\/\/doi.org\/10.1021\/acsbiomaterials.6b00052.","journal-title":"ACS Biomater Sci Eng"},{"issue":"1","key":"1775_CR118","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00204-020-02940-x","volume":"95","author":"V Vilas-Boas","year":"2021","unstructured":"Vilas-Boas V, Vinken M. Hepatotoxicity induced by nanomaterials: mechanisms and in vitro models. Arch Toxicol. 2021;95(1):27\u201352. https:\/\/doi.org\/10.1007\/s00204-020-02940-x.","journal-title":"Arch Toxicol"},{"issue":"5","key":"1775_CR119","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/(sici)1097-0215(19990301)80:5<764::aid-ijc22>3.0.co;2-j","volume":"80","author":"JC Tonn","year":"1999","unstructured":"Tonn JC, et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer J Int Du Cancer. 1999;80(5):764\u201372. https:\/\/doi.org\/10.1002\/(sici)1097-0215(19990301)80:5%3c764::aid-ijc22%3e3.0.co;2-j.","journal-title":"Int J Cancer J Int Du Cancer"},{"issue":"5","key":"1775_CR120","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/toxins12050309","volume":"12","author":"HJ Layfield","year":"2020","unstructured":"Layfield HJ, et al. Repurposing Cancer Drugs Batimastat and Marimastat to Inhibit the Activity of a Group I Metalloprotease from the Venom of the Western Diamondback Rattlesnake, Crotalus atrox. Toxins (Basel). 2020;12(5):309. https:\/\/doi.org\/10.3390\/toxins12050309.","journal-title":"Toxins (Basel)"},{"issue":"5","key":"1775_CR121","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/00000658-200005000-00004","volume":"231","author":"RE Jimenez","year":"2000","unstructured":"Jimenez RE, et al. Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control. Ann Surg. 2000;231(5):644\u201354. https:\/\/doi.org\/10.1097\/00000658-200005000-00004.","journal-title":"Ann Surg"},{"issue":"1","key":"1775_CR122","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12967-018-1650-0","volume":"16","author":"K Tian","year":"2018","unstructured":"Tian K, et al. p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification. J Transl Med. 2018;16(1):282. https:\/\/doi.org\/10.1186\/s12967-018-1650-0.","journal-title":"J Transl Med"},{"issue":"17","key":"1775_CR123","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1177\/1535370216654224","volume":"241","author":"G Bao","year":"2016","unstructured":"Bao G, et al. Glycoprotein non-metastaticmelanoma protein B promotes glioma motility and angiogenesis through the Wnt\/\u03b2-catenin signaling pathway. Exp Biol Med. 2016;241(17):1968\u201376. https:\/\/doi.org\/10.1177\/1535370216654224.","journal-title":"Exp Biol Med"},{"issue":"2","key":"1775_CR124","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11060-010-0158-0","volume":"100","author":"Q Liu","year":"2010","unstructured":"Liu Q, et al. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol. 2010;100(2):165\u201376. https:\/\/doi.org\/10.1007\/s11060-010-0158-0.","journal-title":"J Neurooncol"},{"issue":"9","key":"1775_CR125","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.3390\/ijms22094297","volume":"22","author":"MT Ferreira","year":"2021","unstructured":"Ferreira MT, et al. Cyclooxygenase Inhibition Alters Proliferative, Migratory, and Invasive Properties of Human Glioblastoma Cells In Vitro. Int J Mol Sci. 2021;22(9):4297. https:\/\/doi.org\/10.3390\/ijms22094297.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"1775_CR126","doi-asserted-by":"publisher","first-page":"8395","DOI":"10.3390\/ijms21218395","volume":"21","author":"FDC Souza","year":"2020","unstructured":"Souza FDC, Ferreira MT, Colquhoun A. Influence of Lipoxygenase Inhibition on Glioblastoma Cell Biology. Int J Mol Sci. 2020;21(21):8395. https:\/\/doi.org\/10.3390\/ijms21218395.","journal-title":"Int J Mol Sci"},{"key":"1775_CR127","doi-asserted-by":"publisher","unstructured":"Toth M, Sohail A, Fridman R.\u00a0Assessment of Gelatinases (MMP-2 and MMP-9) by Gelatin Zymography, in Metastasis Research Protocols, M. Dwek, S.A. Brooks, and U. Schumacher, Editors. 2012, Humana Press: Totowa, NJ. p. 121\u2013135. https:\/\/doi.org\/10.1385\/1-59259-136-1:163","DOI":"10.1385\/1-59259-136-1:163"},{"issue":"4","key":"1775_CR128","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/cam4.219","volume":"3","author":"A Torsvik","year":"2014","unstructured":"Torsvik A, et al. U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. Cancer Med. 2014;3(4):812\u201324. https:\/\/doi.org\/10.1002\/cam4.219.","journal-title":"Cancer Med"},{"issue":"17","key":"1775_CR129","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1039\/C4CS00487F","volume":"44","author":"TL Moore","year":"2015","unstructured":"Moore TL, et al. Nanoparticle colloidal stability in cell culture media and impact on cellular interactions. Chem Soc Rev. 2015;44(17):6287\u2013305. https:\/\/doi.org\/10.1039\/C4CS00487F.","journal-title":"Chem Soc Rev"},{"issue":"4","key":"1775_CR130","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/cam4.104","volume":"2","author":"I Ulasov","year":"2013","unstructured":"Ulasov I, et al. Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas. Cancer Med. 2013;2(4):457\u201367. https:\/\/doi.org\/10.1002\/cam4.104.","journal-title":"Cancer Med"},{"issue":"8","key":"1775_CR131","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.3390\/ijms25084554","volume":"25","author":"R Alves","year":"2024","unstructured":"Alves R, et al. Batimastat Induces Cytotoxic and Cytostatic Effects in In Vitro Models of Hematological Tumors. Int J Mol Sci. 2024;25(8):4554. https:\/\/doi.org\/10.3390\/ijms25084554.","journal-title":"Int J Mol Sci"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01775-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01775-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01775-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T16:44:30Z","timestamp":1751388270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01775-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":131,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1775"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01775-8","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"18 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}